Brief: Poxel Announces Positive Results from a Preclinical Study for PXL065, a Proprietary Deuterium-Stabilized R-Stereoisomer of Pioglitazone, in Hypertrophic Cardiomyopathy
20/03/2025 21:08
March 20 (Reuters) - Poxel SA POXEL.PA: POXEL ANNOUNCES POSITIVE RESULTS FROM A PRECLINICAL STUDY FOR PXL065, A PROPRIETARY DEUTERIUM-STABILIZED R-STEREOISOMER OF PIOGLITAZONE, IN HYPERTROPHIC CARDIOMYOPATHY Source text: ID:nBw6LCJTLa Further company coverage: POXEL.PA ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Poxel SA
See all newsFrance's Poxel Q3 revenue rises on higher TWYMEEG royalties
France's Poxel Q2 revenue rises on higher TWYMEEG royalties
France's Poxel Q1 revenue rises 20% on TWYMEEG sales
Brief: Poxel Announces That A Combined General Meeting Will Be Held On December 11, 2025 And The Availability Of The Preparatory Documents
Brief: Poxel Says Cash Runway Estimated Between Mid To End Q2 2025